While their emerging markets have increase nicely, their overall organic sales are dropping. We've seen this to many times. I still feel that at this point all these 'tailwin' companies are grabbing emerging countries while losing the developed countries.
SNY said Thursday it does not expect to meet a production milestone that would have triggered a $1 payout to holders of the contingent value right (CVR) of recently acquired Genzyme Corp.
The $1 milestone is tied to production levels of two Genzyme drugs: Fabrazyme agalsidase beta for Fabry's disease and Cerezyme imiglucerase for Gaucher's disease. Sanofi does not expect to meet end-of-year supply goals for Fabrazyme. Sanofi did say it is supplying Cerezyme globally at normal dosing levels.
Market Data 
Markets 
AI
